# Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine

Source: https://onco.cc/institutions/baylor-duncan/  
OnCo record `baylor-duncan` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Baylor's Duncan Comprehensive Cancer Center sits in Houston's Texas Medical Center; its Center for Cell and Gene Therapy pioneered virus-specific T cells and ran the first GD2 CAR-T trial in neuroblastoma in 2008, and its genome centre sequenced tumours for The Cancer Genome Atlas.

## Summary

NCI-designated in 2007 and comprehensive since 2015, the Duncan Comprehensive Cancer Center sits beside MD Anderson in Houston's Texas Medical Center and works through Baylor St. Luke's, Texas Children's and the Michael E. DeBakey VA hospitals. Its Center for Cell and Gene Therapy (Malcolm Brenner, Helen Heslop, Cliona Rooney) pioneered virus-specific T cells, multi-antigen T cells and, in 2008, the first GD2 CAR-T trial in neuroblastoma; it spun out several cell therapy companies. The Human Genome Sequencing Center under Richard Gibbs sequenced tumours for The Cancer Genome Atlas, and the Lester and Sue Smith Breast Center (Kent Osborne, Matthew Ellis, Rachel Schiff) is a leader in endocrine resistance.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Duncan Cancer Center
- City: Houston, TX, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://www.bcm.edu/

## Sources

- Dan L Duncan Comprehensive Cancer Center (page moved; nearest live section): https://www.bcm.edu/

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- targets: [GD2 (disialoganglioside)](https://onco.cc/targets/gd2/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Texas Children's Cancer and Hematology Center](https://onco.cc/institutions/texas-childrens/)
- people: [Pavan Reddy](https://onco.cc/people/pavan-reddy/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer](https://onco.cc/key-papers/paper-burstein-tnbc-genomic-subtypes-ccr-2015/)

---
JSON: https://onco.cc/api/v1/entities/baylor-duncan.json